The insulin-like growth factor system as a potential therapeutic target in gastrointestinal stromal tumors.
Open Access
- 28 October 2008
- journal article
- review article
- Published by Informa UK Limited in Cell Cycle
- Vol. 7 (19), 2949-2955
- https://doi.org/10.4161/cc.7.19.6760
Abstract
The majority of gastrointestinal stromal tumors (GISTs) are characterized by oncogenic gain-of-function mutations in the receptor tyrosine kinase (RTK) c-KIT with a minority in PDGFRa. Therapy for GISTs has been revolutionized by the use of the selective tyrosine kinase inhibitor imatinib mesylate (IM). For the subset (~10-15%) of GISTs that lack oncogenic mutations in these receptors, the genetic changes driving tumorigenesis are unknown. We recently reported that the gene encoding the insulin-like growth factor 1 receptor (IGF-1R) is amplified in a subset of GISTs, and the IGF-1R protein is over-expressed in WT and pediatric GISTs. In this report we present a more complete picture of the involvement of components of the insulin-like growth factor-signaling pathway in the pathogenesis of GISTs. We also discuss how the IGF pathway may provide additional molecular targets for the treatment of GISTs that respond poorly to IM therapy.Keywords
This publication has 62 references indexed in Scilit:
- Blockade of IGF-1 receptor tyrosine kinase has antineoplastic effects in hepatocellular carcinoma cellsBiochemical Pharmacology, 2006
- Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trialThe Lancet, 2004
- Mechanisms of oncogenic KIT signal transduction in primary gastrointestinal stromal tumors (GISTs)Oncogene, 2004
- Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma GroupEuropean Journal Of Cancer, 2004
- Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal TumorJournal of Clinical Oncology, 2003
- An anti-insulin-like growth factor I receptor antibody that is a potent inhibitor of cancer cell proliferation.2003
- Reduced circulating insulin-like growth factor I levels delay the onset of chemically and genetically induced mammary tumors.2003
- The prognostic value of insulin-like growth factor-I in breast cancer patients. Results of a follow-up study on 126 patientsEuropean Journal Of Cancer, 1994
- Relaxation of insulin-like growth factor II gene imprinting implicated in Wilms' tumourNature, 1993
- Presence and characterization of insulin-like growth factor 1 receptors in human benign breast diseaseEuropean Journal of Cancer and Clinical Oncology, 1988